> For the complete documentation index, see [llms.txt](https://docs.finngen.fi/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://docs.finngen.fi/finngen-data-specifics/expansion-area-3-ea3-projects/ea3-study-immune-mediated-diseases.md).

# EA3 study: Immune-mediated diseases

{% hint style="info" %}
If you wish to use EA3 data, please familiarize yourself with [these instructions](/finngen-data-specifics/expansion-area-3-ea3-projects.md).
{% endhint %}

### Sandbox directory

#### Latest version

`/finngen/library-red/EA3_IMMUNE_MEDIATED_DISEASES_IBD_1.0/`

`/finngen/library-red/EA3_IMMUNE_MEDIATED_DISEASES_RHEUMA_1.0/`

### Study description

Expansion Area 3 (EA3) studies aim to acquire additional clinical data centered around specific diseases through biobanks.

**Aim:** The immune-mediated diseases deep phenotyping study aimed to investigate the genetic background of different phenotypes in rheumatic diseases and inflammatory bowel diseases (IBD), as well as evaluate genetic impact on disease risk and prediction, disease progression and treatment responses. Rheumatoid diseases and IBD can be both categorized as inflammatory diseases and they share similar disease mechanisms. Therefore, the study aims to evaluate the pleiotropy between these disease entities.

**Methods:** Data was captured from five biobanks, Auria, Helsinki, Borealis, Central Finland, and Eastern Finland biobanks. Laboratory database searches were done for laboratory measurements used for assessing diseases activity, and for drugs administrated in hospitals (infliximab, belimumab, rituximab, abatacept, tocilizumab, ustekinumab, and vedolizumab).

**Data:** The Immune-mediated diseases data has been placed in the Sandbox and is available for analysis. Samples are from DF11 and the data has been collected from 5/6 hospital biobanks. Data collection time 14.3.2013-14.3.2023.

### Study variables for rheumatic diseases

**ICD-10 diagnosis codes included:**

* M05-M09 rheumatoid arthirites and related conditions
* M30 polyarteritis nodosa and related diseases
* M31.3 granulomatous polyangiitis
* M31.5 temporal arteritis
* M32 SLE
* M33 dermatopolymyositis
* M34 systemic sclerosis
* M35.0 Sjögren
* M45 ankylosing spondylitis
* M46.1 sacroilitis
* M79.7 fibromyalgia

**Laboratory measurements:**

* S/P-RF
* S/P-CCPAb
* Ly-HLAB27
* P-C3, P-C4
* S-MPOAbG
* S-Pr3Ab
* ANA-ab
* ENA-ab
* s-DNAnAb
* ANA-ty
* S-ANCA
* B-PVK+T and B-TVK (=WBC)
* B-La
* S/P-CRP; S-hCRP

**Hospital-administrated drugs:**

* infliximab
* belimumab
* rituximab
* abatacept
* tocilizumab

### Study variables for inflammatory bowel diseases (IBD)

**ICD-10 diagnosis codes included:**

* K50
* K51
* K52

**Laboratory measurements:**

* S/P-ASAT, ALAT, AFOS and GT
* S/P-Alb
* F-Calpro
* S-Krea; P-Krea (estimated GFR, CKD-Epi)
* S/P-Amyl
* S/P-ANCA
* B-PVK+T and B-TVK (=WBC)
* B-La
* S/P-CRP; S-hCRP
* Bil
* TT%

**Hospital-administrated drugs:**

* infliximab
* ustekinumab
* vedolizumab

**Summary of the data (Oct 2023):**

<figure><img src="/files/qKHOVpUqTQuLpRbclOYZ" alt=""><figcaption></figcaption></figure>